Penbrook Management LLC Acquires 21,000 Shares of Aquestive Therapeutics, Inc. $AQST

Penbrook Management LLC boosted its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 93.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,585 shares of the company’s stock after acquiring an additional 21,000 shares during the quarter. Penbrook Management LLC’s holdings in Aquestive Therapeutics were worth $144,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Summit Wealth & Retirement Planning Inc. bought a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at $29,000. USAdvisors Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $33,000. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at $33,000. Finally, First National Bank & Trust Co. of Newtown bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $50,000. 32.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AQST has been the topic of several research analyst reports. JMP Securities increased their target price on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Zacks Research raised shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.71.

Aquestive Therapeutics Trading Up 1.8%

AQST opened at $6.66 on Tuesday. The company’s fifty day moving average price is $4.82 and its two-hundred day moving average price is $3.73. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $6.86. The company has a market cap of $664.14 million, a price-to-earnings ratio of -9.51 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Cassie Jung sold 62,180 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $5.00, for a total value of $310,900.00. Following the completion of the sale, the chief operating officer owned 283,346 shares in the company, valued at $1,416,730. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Barber sold 91,343 shares of the stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $550,798.29. Following the completion of the sale, the chief executive officer owned 923,430 shares of the company’s stock, valued at approximately $5,568,282.90. This represents a 9.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 178,923 shares of company stock worth $1,006,598 over the last quarter. Insiders own 7.85% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.